What does Moderna's melanoma treatment mean for cancer research? We asked 2 local experts

Merck & Co. and Moderna Inc.'s mRNA cancer vaccine, intismeran, showed promise in a late-stage trial for melanoma. The vaccine, combined with Keytruda, delayed melanoma recurrence and metastasis. Moderna's stock more than doubled on the news. Full data is awaited for further analysis.

Moderna and Merck reported positive Phase 3 trial results for their melanoma vaccine, intismeran autogene, combined with Keytruda. The companies did not disclose efficacy figures, but the announcement led to a $45 billion market value increase for Moderna. Analysts are divided, with some praising the results and others cautioning about high expectations and manufacturing challenges. The vaccine is not yet approved, and detailed data will be presented at a future medical meeting.

Moderna's shares rose 10.5% to $153.50 after seven analyst upgrades. Wolfe Research, Barclays, and others raised price targets, with an average increase of 129.9%. Trading volume reached 14.6M shares, and market cap hit $63.0B. Analysts revised outlooks based on new assumptions about Moderna's pipeline or commercial trajectory.

Merck (MRK) shares rose 12.6% after a Phase 3 trial showed intismeran, developed with Moderna, improved outcomes in melanoma when combined with Keytruda. The trial involved 1,137 patients and found statistically significant improvements in recurrence-free and distant-metastasis-free survival. Keytruda generated $31.68B in 2025, nearly half of Merck's sales. The success could extend Keytruda's growth and support its relevance post-patent expiration in 2028, but challenges remain in approval, pric

Moderna's [MRNA] personalized mRNA cancer vaccine, intismeran, met Phase 3 trial endpoints, boosting its shares and Merck's [MRK] as it's administered with Keytruda. Illumina [ILMN] and Pacific Biosciences [PACB] also rose due to their sequencing technology's role. BioNTech [BNTX] gained as investors reassessed mRNA cancer therapies. Moderna reported Q2 revenue of $145M and a net loss of $782M, while Illumina reported Q2 revenue of $1.16B and raised 2026 guidance. BioNTech reported Q2 revenue of

MRK and MRNA's intismeran autogene showed positive Phase 3 results in melanoma, beating Keytruda alone on recurrence-free survival. BNTX rose 21.6%, ILMN 15.6%, PACB 5.8%, RGEN and DHR also mentioned. Analysts project varying revenue forecasts for the therapy. Keytruda's U.S. patent cliff is in 2028, with 2025 sales at $31.641B.